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Abstract: The aim of this study was to evaluate the effect of virgin olive oils (VOOs) enriched with
phenolic compounds and triterpenes on metabolic syndrome and endothelial function biomarkers
in healthy adults. The trial was a three-week randomized, crossover, controlled, double-blind,
intervention study involving 58 subjects supplemented with a daily dose (30 mL) of three oils:
(1) a VOO (124 ppm of phenolic compounds and 86 ppm of triterpenes); (2) an optimized VOO
(OVOO) (490 ppm of phenolic compounds and 86 ppm of triterpenes); and (3) a functional olive oil
(FOO) high in phenolic compounds (487 ppm) and enriched with triterpenes (389 ppm). Metabolic
syndrome and endothelial function biomarkers were determined in vivo and ex vivo. Plasma high
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density lipoprotein cholesterol (HDLc) increased after the OVOO intake. Plasma endothelin-1 levels
decreased after the intake of the three olive oils, and in blood cell cultures challenged. Daily intake
of VOO enriched in phenolic compounds improved plasma HDLc, although no differences were
found at the end of the three interventions, while VOO with at least 124 ppm of phenolic compounds,
regardless of the triterpenes content improved the systemic endothelin-1 levels in vivo and ex vivo.
No effect of triterpenes was observed after three weeks of interventions. Results need to be confirmed
in subjects with metabolic syndrome and impaired endothelial function (Clinical Trials number
NCT02520739).
Keywords: olive oil; virgin olive oil; olive oil polyphenols; maslinic acid; oleanolic acid;
cardiovascular diseases; endothelial function; phenolic compounds; triterpenes; metabolic syndrome
1. Introduction
Metabolic syndrome (MS) is a cluster of associated metabolic and clinical disturbances that
tend to occur together [1]. This syndrome is commonly represented by the combination of obesity
(particularly abdominal), hyperglycemia, dyslipidemia, and hypertension [2]. MS is associated with
an increased risk of cardiovascular disease (CVD), which is the main cause of disability and mortality
in industrialized countries, and is associated with a chronic inflammatory response characterized by
abnormal cytokine production leading to endothelial dysfunction [3].
There is consolidated clinical evidence that the Mediterranean diet (MD) is associated with
a lower risk of CVDs, including myocardial infarction, stroke and cardiovascular death [4].
Mayneris-Perxachs et al. [5] proposed the MD as a successful tool for the prevention and treatment of
MS and related comorbidities. A large study in a high cardiovascular risk population has found that the
MD supplemented with virgin olive oil (VOO) protects people from vascular disease, suggesting a key
role of olive oil [6]. A recent systematic review and meta-analysis provided evidence that olive oil might
exert beneficial effects on endothelial function and biomarkers of inflammation, thus representing a key
ingredient contributing to the MD cardiovascular-protective effects [7]. Olive oil is not only a source of
monounsaturated fatty acids (MUFAs) but also an important source of bioactive compounds, such as
phenols and triterpenes [8,9]. Previous studies suggested a protective effect of olive oil phenolic
compounds on endothelial dysfunction [10], whereas olive oil triterpenes could be useful for the
prevention of multiple diseases related to cell oxidative damage [11]. Maslinic and oleanolic acids
are the principal triterpenes found in VOO. The potential of these olive oil triterpenic acids for use as
a therapeutic strategy to improve vascular function and treating CVD has been recently reviewed [12].
However, to our best knowledge, no clinical trial has been performed to provide evidence of their
benefits in healthy adults, according to EFSA requirement [13]. The present study which acronyms is
NUTRAOLEUM, aimed to evaluate the effect of VOO enriched with bioactive compounds, such as
phenolic compounds and triterpenes, on MS and endothelial function biomarkers in healthy adults.
We reported that daily intake of VOO enriched in phenolic compounds during three weeks improved
plasma high density lipoprotein cholesterol levels (HDLc), one of the features of metabolic syndrome,
although no differences were found at the end of the three interventions. In addition, VOO with at
least 124 ppm of phenolic compounds, regardless of the triterpenes content, improved the systemic
endothelin-1 levels in vivo and ex vivo, while no additional effect of triterpenes was observed.
2. Materials and Methods
2.1. Subjects
Information about subjects, sample size and their eligibility and dietary control have been
referenced in detail elsewhere [14]. In brief, fifty-eight intention-to-treat subjects were eligible.
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The inclusion criteria were as follows: people in good health on the basis of a physical examination and
basic biochemical and hematological analyses, and willingness to provide written informed consent.
The exclusion criteria were as follows: smoking, intake of antioxidant supplements, aspirin or any
other drug with established antioxidant properties, hyperlipidemia, obesity (body mass index (BMI)
>30 kg/m2), diabetes, hypertension, celiac or other intestinal disease, any condition limiting mobility,
life-threatening diseases, or any other disease or condition that would impair compliance. Five subjects
declined to participate for personal reasons before olive oil type allocation. Fifty-three subjects (27 men
and 26 women) aged from 20 to 50 years from the general population of Granada were enrolled in the
study from February 2014 to July 2014 and were assigned into groups. Two subjects did not complete
the study. After the first intervention, one subject refused to continue for personal reasons, and the
other did not follow the protocol correctly. At the end of the experimental period, 51 subjects remained
in the study (Figure 1) [14]. All subjects provided written informed consent according to the principles
of the Declaration of Helsinki, and the local institutional review board, the Ethics Committee Research
Centre of Granada, approved the protocol (13/11 C38).
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2.2. Study Design
The NUTRAOLEUM study has been designed to evaluate the effects of VOO high in phenolic
compounds and enriched with triterpenes, maslinic and oleanolic acids, from olive exocarp,
on MS features and endothelial function risk biomarkers in comparison with a standard VOO.
The characteristics of the olive oils used in the study, the design of the study, and the detailed
study procedures of the sustained consumption study have been previously published [14]. In brief,
the trial was a randomized, crossover, controlled and double-blind clinical trial involving three oils:
(1) an optimized VOO high in phenolic compounds (OVOO) (490 ppm of phenolic compounds and
86 ppm of triterpenes) produced from Picual olives (Andalucía, Spain); (2) a functional olive oil (FOO),
that was the same OVOO high in phenolic compounds (487 ppm) and enriched with triterpenes
(389 ppm) from olive exocarp; and (3) a VOO obtained from the OVOO after washing to eliminate
the majority of phenolic compounds (124 ppm of phenolic compounds and 86 ppm of triterpenes).
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San Francisco de Asís Cooperative (Montefrío (Granada), Spain) provided the olive oils used in the
present study. Daily doses of 30 mL of the three types of raw olive oils, as recommended by the
US Food and Drug Administration [15], were distributed over three meals. Olive oils were blindly
prepared in special containers; the three types of olive oil were labeled “A”,”B”, and “C”. Containers
with the corresponding 30 mL olive oil daily dose and enough amount of the same oil for cooking
during each intervention period were delivered to the subjects at the beginning of each intervention
period. The subjects were randomly assigned to three orders of administration of olive oil, paired
by gender and age, using the block-randomization method of a software program for sequence
generation [14]. The randomization lists were concealed in a lightproof sealed envelope. The sealed
envelopes were kept by the independent statistician during the study, avoiding the breaking of the
seal. Thus, the subjects, investigators, and outcome assessors were blinded and could not foresee
the treatment allocation throughout the study. Hence, blinding of outcome assessment was also
ensured. According to previous published studies, olive oils were sequentially administered over three
periods of 3 weeks [16] preceded by two weeks of washout periods [17] during which the subjects
were requested to avoid olives and olive oil consumption. A nutritionist personally advised subjects
on replacing all types of habitually consumed raw fats using only the assigned oil. The advantage
of using a crossover design is that each subject served as his or her own control. Olive oils were
specially prepared for the trial and differed only in phenolic compound and triterpenes contents
(Table 1). The oils were prepared in dark, sealed containers and were similar in appearance and
color, thus ensuring blinding of the subjects and study personnel. The trial has been registered at
ClinicalTrials.gov ID: NCT02520739.
Table 1. Characteristics of the administered olive oils.
VOO OVOO FOO
Fatty Acid Profile (%)
C18:0 2.3 2.2 2.1
C18:1n9 78.9 78.2 78.4
C18:2n6 6.6 6.8 6.9
C18:3n3 0.6 0.7 0.7
C20:0 0.4 0.4 0.4
C20:1 0.3 0.4 0.4
C22:0 0.1 0.1 0.1
C24:0 <0.1 <0.1 <0.1
Total phenolic compounds (ppm) 124 490 487
Hydroxytyrosol and derivates 105 424.0 423.0
Lignanes 18.2 61.3 59.2
Flavonoids 0.7 3.4 3.2
Simple phenols 0.0 0.9 0.9
Total triterpenes (mg/kg) 86.5 86.3 388.8
Maslinic acid 47.3 47.3 217.7
Oleanolic acid 39.2 39.1 171.1
Ursolic acid <10 <10 <10
α-tocopherol (ppm) 174 183 176
Squalene (mg/100 g) 529.2 536.2 545.5
Total pigments (ppm) 15.73 17.59 16.78
Total carotenoid pigments (ppm) 7.08 6.79 6.97
Total sterols (ppm) 1437 1396 1460
FOO, functional olive oil; OVOO, optimized virgin olive oil; VOO, virgin olive oil.
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2.3. Evaluation of Dietary Intake
Subjects completed a 3-day dietary record at baseline and during each intervention period [18].
Energy consumption and dietary intakes of macro- and micronutrients data were processed using CSG
software (General ASDE) and the Spanish Food Composition Database (BEDCA) for the subjects who
completed the intervention [19].
2.4. Blood Sample Collection
Fasting venous blood samples were collected at the beginning of the study (baseline) and before
(pre-intervention, after the washout period) and at the end (post-intervention) of each olive oil
intervention period using EDTA-coated tubes. Three-milliliter aliquots were stored at 4 ◦C for the
ex vivo experiments. The rest of the blood samples were centrifuged (4 ◦C, 10 min at 1750× g),
and plasma aliquots were immediately frozen and stored at −80 ◦C until analysis.
2.5. Ex-Vivo Whole Blood Cultures
An aliquot of blood samples (as indicated above) were collected using lithium–heparin tubes
(BD Vacutainer System, Heidelberg, Germany) from a subsample of 36 subjects. Blood was diluted
1:3 with Dulbecco’s modified Eagle’s medium and agitated gently in 3-mL tubes (Greiner Bio-one,
Solingen, Germany) within 3 h after collection. One-milliliter aliquots were seeded in each well of
24-well plates (Nunc, VWR International GmbH, Langenfeld, Germany) and cultured for 24 h at 37 ◦C
under an atmosphere of 5% CO2. From each blood drawing, we performed triplicate incubations in
parallel with positive and negative controls, separate cultures that included phytohaemagglutinin
(PHA, 10 µg/mL), E. coli lipopolysaccharide (LPS, 1 µg/mL) and phorbol 12-myristate 13-acetate plus
ionomycin (PMA, 25 ng/mL + IO, 1 µg). The same lots of PHA, LPS, PMA + IO and phosphate buffered
saline were used in all experiments. Blood cultures were removed from each well and centrifuged at
700× g for 5 min at 20 ◦C. The resulting supernatants (plasma) were aliquoted and pooled from eight
subjects from each of the three assigned orders of administration of olive oil and stored at −20 ◦C until
further analysis of endothelin-1 [20,21].
2.6. Measurement of Metabolic Syndrome Biomarkers
In the fasting state, anthropometric measurements (weight, height and waist circumference)
were determined at baseline and before and after each intervention period by the same member of
the professional staff. For all measurements, the subjects did not wear shoes. MS biomarkers were
determined as primary outcomes. BMI was calculated as weight (kg) divided by height squared (m2).
Total cholesterol, triacylglycerols and serum glucose were determined by standard enzymatic methods
using a PENTRA-400 autoanalyzer (ABX-Horiba Diagnostics, Montpellier, France). Plasma HDLc was
measured as soluble HDLc as determined using an accelerator selective detergent method (ABX-Horiba
Diagnostics). Plasma low density lipoprotein cholesterol (LDLc) concentrations were calculated using
the Friedewald formula. Systolic (SBP) and diastolic (DBP) blood pressures were measured with
a mercury sphygmomanometer after a minimum of 10 min resting in the seated position; the average
of two measurements was recorded. The pulse pressure was calculated as the difference between SBP
and DBP. Total cholesterol, triacylglycerols, serum glucose, HDLc and LDLc could only be measured
for 46 subjects.
2.7. Measurement of Selected Plasma Hormones and Endothelial Function Biomarkers
A Milliplex Map Kit, human monoclonal antibody kits (EMD Millipore Corporation, Billerica,
MA, USA) were used according to the manufacturer’s instructions in conjunction with a Luminex®
200 system with the XMap technology (Luminex Corporation, Austin, TX, USA) to determine the
concentrations of the following biomarkers as secondary outcomes: adiponectin (coefficient of variation
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(CV): 10.3%), resistin (CV: 7.7%), soluble intercellular adhesion molecule (sICAM-1) (CV: 6.1%) and
soluble vascular adhesion molecule (sVCAM-1) (CV: 5.4%), (Cat. #HADK1MAG-61K).
Endothelin-1 was determined as a secondary outcome by ELISA (CV): 7.2%) (R&D Systems,
Minneapolis, MN, USA; Cat. DET100) in both plasma and whole blood culture supernatants.
2.8. Measurements of Triterpenes and Phenolic Compounds in Urine
To ensure the subjects’ compliance with the assigned intervention, triterpenes (maslinic and
oleanolic acid) derivatized with 2-picolylamine (see Appendix A) and olive oil phenolic compounds
(hydroxytyrosol and metabolites) were analyzed in 24-h urine from 12 random subjects by liquid
chromatography coupled to a mass spectrometer [22].
2.9. Statistical Analysis
Baseline data are presented as the mean values ± standard error of the mean (SEMs) unless
otherwise indicated. The normality of variables was assessed using Q-Q graphs. The χ2 test was used
for categorical variables to determine differences in the baseline. One-factor ANOVA or Kruskal-Wallis
tests were used (depending on whether the normality assumption was met) for continuous variables
to determine differences among the three olive oil interventions, in terms of baseline characteristics,
nutrient intake and for the ex vivo endothelin-1 experiment.
Biochemical parameters are presented as adjusted mean values ± SEMs and were analyzed
using a linear mixed-effects model (LMM). The normality of the residues was evaluated using Q-Q
graphs. Missing data were imputed using appropriate methods. The outliers for each intervention
were removed if kurtosis > 1 and asymmetry > 1 in the distribution of the responses. In all cases, more
than 80% of the data were analyzed.
Variables with a skewed distribution were logarithm-transformed for analysis (nutritional
variables and resistin). A LMM was used to compare variables before and after each intervention
(pre- vs. post-interventions, intra-treatment effect) and to compare the results between the groups
after the 3-week intervention (inter-treatment effect), adjusting for age, gender, pre-intervention
and period as fixed effects and for subjects and hospital as random effects. The same model was
also used to compare changes of the variables (post-intervention minus pre-intervention) without
adjusting for pre-intervention. Carryover effects were assessed as the interaction between period and
intervention [23]. The multiple comparison post hoc is given by the estimated means in the model
(adjusted by Sidak). This statistical model (LMM) takes into account all the possible confounders
(covariates) which are included on it. In addition, the baselines are used as outcomes but without effect,
so they can act as a control and take into account a possible carryover effect [24]. Within the LMMs,
the factor treatment, time and the random effect considered by participant are taken into account in
the structure of the data.
In addition, an interaction term was checked for differences on the effect part intervention by
gender. Model goodness-of-fit was tested using residual plots. The Bayesian Information Criterion
was used to assess model reduction and the selection of variables and interactions. We performed all
analysis on an intention-to-treat basis. A p < 0.05 value was considered significant. Statistical Package
for the Social Sciences version 20 software was used to perform the statistical analysis (SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Baseline Characteristics
Tables 2 and 3 show the clinical and biochemical characteristics, and the average daily nutritional
intakes, respectively, of the subjects grouped according to the sequence of olive oil administration at the
beginning of the study. No differences were observed among the three groups of subjects at baseline.
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Table 2. Clinical and biochemical characteristics of subjects at baseline according to olive oil
administration sequence.
Characteristics Sequence 1 Sequence 2 Sequence 3
Age, years 32 ± 2 29 ± 2 28 ± 2
Gender, male n (%) 12 (60) 10 (53) 8 (42)
BMI, kg/m2 24 ± 1 24 ± 1 24 ± 1
Waist circumference, cm 80 ± 2 78 ± 3 77 ± 2
Males 80 ± 3 82 ± 4 82 ± 2
Females 81 ± 5 73 ± 3 73 ± 2
HDLc, mg/dL 58 ± 2 58 ± 3 59 ± 2
Males 55 ± 3 51 ± 3 52 ± 3
Females 64 ± 2 65 ± 5 64 ± 3
LDLc, mg/dL 117 ± 9 107 ± 7 102 ± 5
Total cholesterol, mg/dL 192 ± 10 180 ± 7 175 ± 7
Triacylglycerols, mg/dL 87 ± 7 81 ± 13 67 ± 5
Glucose, mg/dL 90 ± 2 92 ± 2 87 ± 2
Adiponectin, mg/L 11.40 ± 1.38 12.49 ± 1.69 17.20 ± 2.78
Resistin, µg/L 16.38 ± 1.88 16.57 ± 1.82 15.26 ± 1.69
SBP, mmHg 121 ± 2 120 ± 3 118 ± 3
DBP, mmHg 77 ± 2 74 ± 2 71 ± 2
Pulse pressure, mmHg 44 ± 2 46 ± 3 47 ± 2
Endothelin-1, pg/mL 1.35 ± 0.08 1.36 ± 0.10 1.38 ± 0.12
sICAM, ng/mL 74.48 ± 4.50 62.26 ± 3.16 66.10 ± 4.63
sVCAM, ng/mL 459 ± 21 459 ± 30 443 ± 25
Values are expressed as the means ± SEMs. ANOVA and χ2 tests were used to compare results between groups.
Sequence 1: OVOO, VOO and FOO olive oil, n = 20; Sequence 2: VOO, FOO and OVOO olive oil, n = 19; Sequence 3:
FOO, OVOO and VOO olive oil, n = 19. BMI, body mass index; DBP, diastolic blood pressure; FOO, functional
olive oil; HDLc, high density lipoprotein cholesterol; LDLc, low density lipoprotein cholesterol; n, number of
observations; OVOO, optimized virgin olive oil; SBP, systolic blood pressure; SEM, standard error of the mean;
sICAM-1, soluble intercellular adhesion molecule; sVCAM-1, soluble vascular cell adhesion molecule; VOO, virgin
olive oil.
Table 3. Average daily energy and selected nutrient intake of subjects at baseline according to olive oil
administration sequence.
Nutritional Characteristics Sequence 1 Sequence 2 Sequence 3
Energy, kcal 1976 ± 90 2151 ± 138 2074 ± 109
Total carbohydrates, g 200 ± 10 213 ± 16 214 ± 13
Proteins, g 80 (16–222) 96 (37–258) 93 (21–215)
Total fat, g 86 ± 4 102 ± 10 89 ± 6
MUFA, g 31 (12–80) 33 (6–85) 33(6–89)
PUFA, g 13 (3–43) 11 (1–44) 14 (2–49)
SFA, g 21 (6–64) 27 (11–80) 26 (4–66)
Vitamin A, µg retinol equivalents 440 (111–1552) 512 (109–158) 539 (7–1669)
Vitamin C, mg ascorbic acid 70 (4–400) 88 (11–428) 81 (3–335)
Vitamin D, µg 2 (0–41) 2 (0–40) 2 (0–34)
Vitamin E, mg α-tocopherol equivalents 9 (2–29) 9 (1–67) 11 (1–39)
Cholesterol, mg 284 ± 26 354 ± 31 287 ± 24
Alcohol, g 0 (0–52) 0 (0–48) 0 (0–84)
Selenium, µg 31 (5–130) 34 (1–114) 36 (3–117)
Values are expressed as the means ± SEMs or as medians (range). ANOVA was used to compare results between
groups for those variables that followed normality, and the Kruskal Wallis test was used for those that did not. Data
of 51 subjects were obtained from the 3-day dietary record at baseline. Sequence 1: OVOO, VOO and FOO olive oil,
n = 54; Sequence 2: VOO, FOO and OVOO olive oil, n = 42; Sequence 3: FOO, OVOO and VOO olive oil, n = 57.
FOO, functional olive oil; MUFA, monounsaturated fatty acids; n, number of observations; OVOO, optimized virgin
olive oil; PUFA, polyunsaturated fatty acids; SEM, standard error of the mean; SFA, saturated fatty acids; VOO,
virgin olive oil.
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3.2. Nutritional Analysis
Table 4 shows the average daily energy and selected nutrient intakes after the three olive oil
interventions. No differences were observed among the three interventions (Table 4).
Table 4. Average daily energy and selected nutrient intake of subjects after the three olive
oil interventions.
Nutritional Characteristics VOO OVOO FOO
Energy, kcal 1983 (873–4342) 2006 (697–4561) 1914 (780–3457)
Total carbohydrates, g 199 (47–408) 203 (30–531) 175 (38–533)
Proteins, g 77 (24–180) 80 (17–200) 73 (25–207)
Total fat, g 89 (27–244) 94 (24–257) 91 (20–227)
MUFA, g 44 (8–119) 44 (8–113) 45 (9–123)
PUFA, g 11 (4–37) 12 (4–36) 13 (3–41)
SFA, g 25 (7–74) 27 (6–82) 24 (5–69)
Vitamin A, µg retinol equivalents 433 (34–1477) 427 (26–1504) 452 (39–1515)
Vitamin C, mg ascorbic acid 48 (0–280) 60 (0–255) 55 (1–305)
Vitamin D, µg 1.5 (0–32) 1.2 (0–82) 1.2 (0–81)
Vitamin E, mg α-tocopherol equivalents 10 (2–30) 11 (3–32) 11 (2–32)
Cholesterol, mg 285 (11–981) 253 (28–853) 272 (15–1011)
Alcohol, g ethanol 0 (0–97) 0 (0–54) 0 (0–78)
Selenium, µg 30 (0–260) 31 (0–198) 31 (1–160)
Values are expressed as median (range). ANOVA was used to compare intakes between interventions. Data for
51 subjects were obtained from the 3-day dietary record at baseline. Data for 51 subjects were obtained from the
3-day dietary record at baseline. FOO, functional olive oil; MUFA, monounsaturated fatty acids; n, number of
observations; OVOO, optimized virgin olive oil; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids;
VOO, virgin olive oil.
3.3. Plasma Metabolic Syndrome and Endothelial Function Biomarkers
Table 5 shows MS and endothelial function biomarker data before and after the three interventions.
All clinical and biochemical MS biomarkers were within normal values at the beginning and at the end
of the study. BMI, waist circumference, pulse pressure, and fasting plasma glucose, adiponectin and
resistin concentrations were unchanged during the study.
When comparing pre- vs. post-intervention data (intra-treatment effect), HDLc levels significantly
increased only after the OVOO intervention (p = 0.041), and only in females (p = 0.005). However, no
differences were observed between the three interventions. Total cholesterol increased after the FOO
intervention (p = 0.021). LDLc was unaffected. Fasting plasma triacylglycerol concentrations increased
after the VOO and OVOO interventions (p = 0.037 and p = 0.002, respectively) but not after the FOO
intervention. However, plasma triacylglycerols were low at the beginning of the study (78 ± 5 mg/dL).
On the other hand, SBP decreased after the VOO intervention (p = 0.019) and increased after the FOO
intervention (p = 0.004), while DBP and pulse pressure were unchanged after the three interventions.
Plasma endothelin-1 concentrations decreased after the VOO, OVOO, and FOO interventions (p = 0.006,
p = 0.006 and p = 0.014, respectively), and the plasma concentrations of sICAM-1 and sVCAM-1 were
unchanged after the three interventions.
When analyzing the inter-treatment effects, LDLc levels were higher after the FOO intervention
compared with the OVOO intervention (p = 0.033), and SBP was higher after the FOO intervention
compared with the VOO intervention (p = 0.001).
The changes in metabolic clinical variables and endothelial function biomarkers (Supplementary
Table S1) were similar in all the subjects after the three interventions except SBP, which increased up
to 118 mmHg after the FOO but decreased after the VOO and OVOO interventions (up to 115 and
116 mmHg, respectively) (p < 0.001). The results show differences by gender for all interventions.
However, no interactions were observed between gender and intervention.
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Table 5. Metabolic syndrome and endothelial function biomarkers before and after each olive oil intervention in healthy adults.
Characteristics
VOO OVOO FOO
Pre-Intervention Post-Intervention Pre-Intervention Post-Intervention Pre-Intervention Post-Intervention
BMI, kg/m2 23.9 ± 0.1 24 ± 0.1 23.9 ± 0.1 24 ± 0.1 24 ± 0.1 24 ± 0.1
Waist circumference, cm 77.4 ± 0.7 77.2 ± 0.7 77.2 ± 0.7 76.8 ± 0.7 77.4 ± 0.7 76.9 ± 0.7
HDLc, mg/dL 58 ± 2 59 ± 2 57 ± 2 60 ± 2 * 58 ± 2 60 ± 2
Males 52 ± 2 53 ± 2 52 ± 2 52 ± 2 52 ± 2 54 ± 2
Females 64 ± 2 65 ± 2 63 ± 2 67 ± 2 * 65 ± 2 66 ± 2
LDLc, mg/dL 105 ± 4 108 ± 4 a,b 104 ± 4 106 ± 4 a 104 ± 4 111 ± 4 b
Total cholesterol, mg/dL 179 ± 5 182 ± 5 177 ± 5 183 ± 5 178 ± 5 186 ± 5 *
Triacylglycerols, mg/dL 72 ± 7 75 ± 7 * 74 ± 7 81 ± 7 * 75 ± 7 75 ± 7
Glucose, mg/dL 91 ± 2 91 ± 2 91 ± 2 91 ± 2 90 ± 2 91 ± 2
Adiponectin, mg/L 13.74 ± 1.7 12.8 ± 1.7 12.48 ± 1.7 13.6 ± 1.71 12.62 ± 1.71 13.74 ± 1.71
Resistin, µg/L 14.1 ± 1.1 14.1 ± 1.1 14.5 ± 1.1 13.8 ± 1.1 13.8 ± 1.1 14.1 ± 1.1
SBP, mmHg 117 ± 3 115 ± 3 *,a 119 ± 3 116 ± 3 a,b 114 ± 3 118 ± 3 *,b
DBP, mmHg 72 ± 2 72 ± 2 75 ± 2 73 ± 2 72 ± 2 74 ± 2
Pulse pressure, mmHg 45 ± 1 43 ± 1 44 ± 1 42 ± 1 42 ± 1 45 ± 1
Endothelin-1, pg/mL 1.53 ± 0.15 1.38 ± 0.15 * 1.58 ± 0.15 1.41 ± 0.15 * 1.49 ± 0.15 1.35 ± 0.15 *
sICAM-1, ng/mL 68.09 ± 3.19 67.11 ± 3.19 65.17 ± 3.20 67.73 ± 3.19 65.1 ± 3.20 66.7 ± 3.21
sVCAM-1, ng/mL 451 ± 22 443 ± 23 435 ± 22 451 ± 22 431 ± 22 442 ± 23
Values are expressed as the adjusted means ± SEMs. LMM was used to compare pre-intervention vs. post-interventions with each oil data, and data after the three interventions
(post-interventions). * Significant differences between pre-intervention vs. post-intervention data within each intervention with the three olive oils. Different superscript letters indicate
significant differences between post-intervention results (a,b). p < 0.05 was considered significant. DBP, diastolic blood pressure; FOO, functional olive oil; HDLc, high density lipoprotein
cholesterol; LDLc, low density lipoprotein cholesterol; OVOO, optimized virgin olive oil; SBP, systolic blood pressure; SEM, standard error of the mean; sICAM-1, soluble intercellular
adhesion molecule; sVCAM-1, soluble vascular cell adhesion molecule; VOO, virgin olive oil.
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3.4. Plasma Endothelin-1 Ex Vivo Experiments
Before the three interventions, pooled blood cultures challenging with PHA, LPS, or PMA + IO
induced a potent increase in the supernatant concentrations of endothelin-1 in whole blood cultures.
Figure 2 shows that the supernatant endothelin-1 concentration changes (post-intervention minus
pre-intervention data) in whole blood cultures from the subjects were similar after the VOO and
OVOO interventions and were significantly lower after the FOO intervention: −26.7 ± 15.3 pg/mL,
−41.0 ± 12.9 pg/mL, and −119.5 ± 28.5 pg/mL for the VOO, OVOO and FOO interventions,
respectively (p = 0.035), when stimulating with PHA; −30.3 ± 6.5 pg/mL, −58.2 ± 10.1 pg/mL
and −109.6 ± 9.7 pg/mL for the VOO, OVOO, and FOO interventions, respectively, when stimulating
with LPS (p = 0.002); and −38.9 ± 3.4 pg/mL, −50.8 ± 8.5 pg/mL and −87.0 ± 11.1 pg/mL for the
VOO, OVOO, and FOO interventions, respectively, when stimulating with PMA+IO (p = 0.015).
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Figure 2. Plasma endothelin-1 ex vivo changes (post-intervention minus pre-intervention data) when
stimulated with PHA, LPS or PMA + IO in whole blood cultures from healthy adults. Values are
expressed as the means ± SEMs. ANOVA was used to compare differences between interventions
and induction treat ents. The Tukey post-hoc test was used for multiple comparisons among groups.
p < 0.05 as considered significant. FOO, functional olive oil; IO, ionomycin; OVOO, optimized virgin
olive oil; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate; VOO, virgin olive oil.
Supplemental Figure S1 shows the supernatant endothelin-1 concentrations that were induced
ex vivo with PHA, LPS, and PMA + IO in whole blood cultures from the subjects before and after the
three interventions. After the VOO, OVOO, and FOO interventions, challenging with LPS or PMA
+ IO induced a significantly lower increase of endothelin-1 secretion in whole blood cultures, while
challenging with PHA induced a significantly lower increase of endothelin-1 secretion only after the
OVOO and FOO interventions.
3.5. Biomarkers of Intervention Compliance
Recoveries of triterpenes in urine were consistent with the olive oils consumed in each intervention.
Figure 3 shows urinary triterpenes changes (post-intervention minus pre-intervention data) for each
olive oil intervention. The amounts of both triterpenic acids in urine after the FOO intervention were
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about four times higher than those recovered after the VOO and OVOO interventions (p = 0.004 and
p < 0.001, respectively, for maslinic acid, and p = 0.026 and p < 0.001, respectively, for oleanolic acid).
Urine concentrations of total hydroxytyrosol (the sum of hydroxytyrosol and its glucuronide and
sulfate conjugates) were higher after the OVOO (2444 mM, p = 0.003) and FOO (2876 mM, p = 0.002)
interventions than after the VOO (115 mM, p = 0.011) intervention.
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Figure 3. In vivo urinary triterpenes changes (post-intervention minus pre-intervention data) for each
olive oil intervention in healthy adults. Values are expressed as the means ± SEMs. ANOVA was
used to compare differences between the three interventions. Different superscript letters indicate
significant differences between the interventions for oleanolic acid (a,b) and for maslinic acid (c,d).
p < 0.05 was considered significant. FOO, functional olive oil; OVOO, optimized virgin olive oil; VOO,
virgin olive oil.
4. Discussion
The NUTRAOLEUM study is the first human nutritional clinical trial concerning the effects of
VOO that is high in phenolic compounds and enriched with triterpenes, maslinic and oleanolic acids,
from olive exocarp, on MS features and endothelial function risk biomarkers in comparison with
standard VOO in healthy subjects.
The PREDIMED study reported that a MD supplemented with at least 50 g of dietary VOO
caused a reversion of MS after a median follow-up of 4.8 years [25], reducing the rate of CVD events
by 30% compared with a low-fat diet control group [26]. In addition, this MD enriched with VOO
and without energy restrictions reduced the diabetes risk among individuals at high cardiovascular
risk [27]. Consumption of VOO close to 2.7, 164 or 366 ppm/day of phenolic compounds in humans,
a 0.03% of hydroxytyrosol in a rodent model, and 50 ppm/day of hydroxytyrosol in a murine model
have been reported to improve the blood lipid profile, although results in mice were not conclusive [28],
possibly due to differences in the phenolic content of the olive oil and the physio-pathology of the
studied animals. Polyphenols from olive oils have been shown to provide additional benefits on
HDLc, other than those provided by the MUFA content. However, contradictory data exists on these
benefits. In 2015, a meta-analysis reported no effect on HDLc concentration after the intake of VOO
with at least 150 ppm of phenolic compounds [29], while, in accordance with our results, a recent
systematic review [30] concluded that plasma HDLc was increased in different studies consuming
from 2.28 to 75 g/day of olive oil. In the Eurolive Study, a European multicenter study, three olive oils
(refined, medium and high) differing in their phenolic compound content (2.7, 164 and 366 ppm/day of
phenolic content, respectively) increased HDLc and decreased triacylglycerol concentrations [16]. The
increase in HDLc was linear with the olive oil polyphenol content. This additional benefit has also been
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described in healthy and hypercholesterolemic subjects treated with polyphenol-enriched VOO [31]
when excluding patients treated with hypolipidemic medication. Additionally, the increase of olive oil
polyphenols in the lipoprotein fraction may increase HDL size, stability, and antioxidant status [32].
It has been reported that the daily intake of olive oils enriched with its own polyphenols (250 ppm
or 500 ppm), as well as the intake of olive oil enriched in polyphenols from thyme (250 ppm/day)
decrease LDLc and improve the lipoprotein subclass distribution and associated ratios [33]. Other
authors have described that a one-year intervention with a MD enriched with VOO improved several
LDL characteristics related to its atherogenicity (resistance against oxidation, size, composition, and
cytotoxicity) but did not modify the plasma LDLc concentrations in a subsample of subjects at high
cardiovascular risk in the PREDIMED study [34]. Our results are consistent with this null effect of
VOO on LDLc. On the other hand, besides the weak increase in plasma triacylglycerols observed
after interventions with both VOO and OVOO, this was without clinical significance given that levels
were low at baseline and remain low at the end of the three interventions, and thus it did not increase
cardiovascular risk in these healthy subjects (triacylglycerols < 150 mg/dL) [35]. Our results are
in contrast with the triacylglycerol improvement reported in the EUROLIVE Study [16]. A recent
meta-analysis and systematic review focused on high polyphenol VOO concluded no effect on plasma
triacylglycerol concentrations [29]; in addition, Saibandith et al. [36] stated that the effect of olive oil
polyphenols on plasma triacylglycerols remained unclear. However, longer studies are needed to
clarify this issue.
To the best of our knowledge, this is the first clinical trial evaluating the effect of olive
oil triterpenes on plasma lipids and endothelial function biomarkers. Previous animal studies
have reported different effects of oleanolic acid on plasma lipids, depending on the experimental
animal model [37]. Based on our results, FOO enriched with triterpenes did not modify plasma
HDLc, LDLc, or triacylglycerols, but increased plasma total cholesterol concentrations, although
no inter-group significance was found. However, although these modifications do not represent
an increase in cardiovascular risk since the values are low enough to be considered safe (total
cholesterol < 190 mg/dL) [35], further human clinical trials are needed to demonstrate the potential
benefit of olive phenolic compounds and triterpenes on plasma lipid concentrations over longer
intervention periods.
Endothelial dysfunction is a critical early event in the development of atherosclerosis [38].
An imbalance between vasodilating and vasoconstricting molecules, such as nitric oxide and
endothelin-1, respectively, contributes to the pathogenesis of hypertension and its complications [39].
Our results indicate that plasma endothelin-1 levels decreased after the VOO, OVOO and FOO
interventions, and these results were also confirmed throughout ex vivo blood culture experiments.
Although endothelin-1 is mainly produced from vascular endothelial cell, several studies have
suggested that blood cells, such as polymorphonuclear neutrophils [40] and T-Cells [41], and also
macrophages [42] are responsible from circulating levels of endothelin-1. In addition, ex vivo
experiment has demonstrated the release of the mature peptide after LPS and LPS + PMA
stimulation [40]; Mencarelli et al. [43] have confirmed these results. As demonstrated here, endothelin-1
production was decreased after the three interventions. This effect may be beneficial for cardiovascular
risk affected people, since the effect of endothelin-1 has been documented on endothelial and
inflammatory cells, which contributes to pathophysiological processes such as vascular hypertrophy,
cell proliferation, fibrosis and inflammation [44–46]. In humans, the consumption of VOO has shown
benefits on blood pressure and endothelial function [47]. In agreement with our results, a meta-analysis
stated that olive oils with at least 150 ppm of phenolic compounds exert a moderate effect on lowering
SBP and no effects on DBP [29]. Regarding triterpenes, besides the weak SBP increase observed after
this intervention, no clinical significance was observed as blood pressure remained under 130 mmHg
and did not increase cardiovascular risk [35]. It is reported that SBP varies to a greater degree than
DBP [48,49]. For this reason, we calculated pulse pressure and found no significant effect of FOO.
A beneficial effect of triterpenes on endothelial function [50] and blood pressure [51] has been described
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in animal models of hypertension, but further studies are required to explore the mechanisms involved
in the effect of specific components of VOO on endothelin-1 regulation.
In vitro studies showed that minor olive oil components, specifically hydroxytyrosol and its
metabolites, down-regulate the secretion of E-selectin, p-selectin, sICAM-1, and sVCAM-1, affecting
endothelial function [52]. However, and in agreement with our results, no differences in sICAM-1 or
sVCAM-1 plasma concentrations were reported after 50 mL of VOO or refined olive oil consumption
containing (161 or 14.67 ppm/day of phenolic compounds, respectively) in coronary heart disease
patients [53]. Another study found a significant reduction in sICAM-1 but not in sVCAM-1
concentrations after the intake of 50 mL/day of olive oil [54]. Recently, it has been proposed that the
intake of 25 mL/day of VOO containing 366 ppm of phenolic compounds modulates the expression
of several genes related to the renin-angiotensin-aldosterone system [55]. Therefore, further longer
studies are needed to reach final conclusions about the effect of VOO minor compounds on molecules
modulating endothelial function.
One of the limitations of the present study is that young and healthy subjects are recruited as
target population. The present intervention does not appear sufficient to draw definitive conclusions.
Therefore, new studies in older subject affected by metabolic syndrome and endothelial dysfunction
would be interesting in order to evaluate the beneficial effect of VOO components. Although no
differences in dietary intakes were observed during the three interventions, measurements of dietary
intake relied on self-reporting and were therefore subjective. Another limitation of this study is that
dietary records for the washout periods were not recorded, thus we cannot analyzed dietary intakes
during these periods. In addition, our subjects live in the south of Spain, where MD and VOO are
highly consumed. Therefore, a 3-week intervention is not long enough to cause significant changes.
Further studies are required to find conclusions related to the bioactive compounds presents in olive
oils, and to explore the mechanisms involved in these effects of specific components of VOO on MS
and endothelial function.
5. Conclusions
In conclusion, olive oil rich in polyphenols increased HDLc levels in females, although no
differences were found at the end of the three interventions, and improved an endothelial function
biomarker both in vivo and ex vivo. No additional benefits were obtained from triterpenes VOO
enrichment after 3-wk supplementation. However, further longer studies are warranted on olive
oil triterpenes and their health benefits in older subjects particularly in those affected by metabolic
syndrome and endothelial dysfunction.
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Appendix A
Analysis of Triterpenes in Urine
For the analysis of maslinic acid (MA) and oleanolic acid (OA), aliquots of 250 µL of urine
were transferred into 15-mL screw-capped glass tubes and spiked with 1 ng/mL of d3-OA, 20 µL of
β-glucuronidase from Escherichia coli and 200 µL of 0.1 M phosphate buffer pH 6.0. After overnight
incubation in a water bath at 37 ◦C, 50 mg of NaHCO3/Na2CO3 (1:2, w/w) was added to each tube
before extraction. The samples were then subjected to a liquid-liquid extraction with 2 mL of methyl
tert-butyl ether. The mixture was homogenized in a shaker rotator for 20 min and centrifuged at
3500 rpm for 5 min at room temperature. The organic phase was transferred to clean tubes and
evaporated (40 ◦C) under a stream of nitrogen. The extracts were then derivatized with 50 µL
of 2-picolylamine (1 µg/µL in ACN). The reaction mixture was incubated for 10 min at 60 ◦C on
a heating block and then dried under a nitrogen stream. Samples were reconstituted in 100 µL of
ACN-H2O MilliQ grade (1:1). Derivatized OA and MA in urine was quantified using an Acquity
UPLC system, (Waters Associates, Milford, MA, USA) for the chromatographic separation, the column
was coupled to a triple quadrupole (Quattro Premier) mass spectrometer provided with an orthogonal
Z-spray-electrospray interface (ESI) (Waters Associates). Nitrogen was used as the drying and
nebulizing gas. The desolvation gas flow was set to approximately 1200 L/h, and the cone gas
flow was set to 50 L/h.
Capillary voltages of 3 kV and 2.5 kV were used in positive and negative ionization mode,
respectively. The nitrogen desolvation temperature was set to 450 ◦C, and the source temperature was
set to 120 ◦C. The collision gas was argon, and the flow rate was 0.21 mL/min.
The liquid chromatography separation was performed at 55 ◦C using an Acquity CSH
phenyl-hexyl column (100 mm, 2.1 mm i.d., 1.7 µm) (Waters Associates) operating at a flow rate
of 300 µL min−1. Water and methanol, both containing formic acid (0.01% v/v) and ammonium
formate (1 mM), were selected as mobile phase solvents. For the target detection of derivatized OA
and MA, a gradient program was used to separate the analytes; the percentage of organic solvent
was linearly changed as follows: 0 min, 70%; 0.5 min, 70%; 7 min, 98%; 9 min, 98%; 9.5 min, 70%;
and 11 min, 70%.
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